Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was down 5.5% during mid-day trading on Tuesday . The stock traded as low as $23.45 and last traded at $23.01. Approximately 14,342 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 224,916 shares. The stock had previously closed at $24.34.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, Oppenheimer upped their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $46.83.

Dianthus Therapeutics Trading Down 4.6 %

The business’s 50-day simple moving average is $22.56 and its 200 day simple moving average is $25.02. The company has a market capitalization of $687.09 million, a P/E ratio of -9.24 and a beta of 1.82.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd bought a new position in Dianthus Therapeutics during the fourth quarter valued at about $26,000. Quest Partners LLC boosted its position in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Dianthus Therapeutics in the fourth quarter worth approximately $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics during the 4th quarter worth $35,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Dianthus Therapeutics in the 4th quarter worth $59,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.